EGFR and non-small cell lung carcinoma: Prompted by the high prevalence of EGFR mutations in East Asian NSCLC patients and the challenges in managing EGFR‐TKI‐resistant cases,25 we investigated a modified IMpower 150 regimen substituting pemetrexed for paclitaxel and administering bevacizumab at 7.5 mg/kg every 3 weeks to optimise tolerability and minimise toxicity.26